Anti-SMAD2 (phospho T220) Antibody

The SMAD2 protein sits at a critical junction of the TGF-β (transforming growth factor-beta) signal transduction cascade, transmitting signals from activated cell-surface receptors to the nucleus where target gene transcription is regulated. Phosphorylation at threonine 220 (T220) marks an activated state of SMAD2, providing a direct readout of upstream kinase activity and TGF-β pathway engagement in cell lysates.

Produced by Antibodies.com as a rabbit polyclonal IgG preparation, this unconjugated antibody is validated for Western blot (WB) detection of human SMAD2 when phosphorylated at the T220 epitope. The 100 µl vial supplies enough reagent for multiple membrane-probing experiments, making it practical for ongoing pathway studies or for screening panels of treated versus untreated samples.

Research applications include monitoring TGF-β-induced signaling dynamics, profiling SMAD activation kinetics following ligand stimulation, comparing basal versus ligand-induced phospho-SMAD2 levels across cell lines, and characterizing perturbations of the receptor-SMAD axis using small-molecule inhibitors, RNAi knockdowns, or mutant receptor constructs. Because the reagent recognizes a defined phospho-site, it separates the active SMAD2 pool from total SMAD2 on immunoblots, supporting quantitative densitometric analysis after normalization to loading controls such as β-actin or GAPDH.

Storage at -20 °C in working aliquots preserves phospho-specific binding activity and limits damage from repeated freeze-thaw cycles. With reactivity confirmed against human SMAD2, this antibody is appropriate for studies in standard human cell line models relevant to TGF-β biology, including research into fibrosis, epithelial-mesenchymal transition, and related receptor-SMAD signaling contexts.